Document is current
Any future updates will be listed below
-
Authors
Ogasawara, Ken http://orcid.org/0000-0002-4264-8927
Wood-Horrall, Rebecca N.
Thomas, Mark
Thomas, Michael
Liu, Liangang
Liu, Mary
Xue, Yongjun
Surapaneni, Sekhar
Carayannopoulos, Leonidas N.
Zhou, Simon
Palmisano, Maria
Krishna, Gopal
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04231435 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach
https://doi.org/10.1007/s00280-021-04346-7
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 9 April 2021
Accepted: 19 August 2021
First Online: 3 September 2021
Declarations
:
: K.O., Ma.T., Mi.T., L.L, M.L, Y.X, S.S, L.N.C., S.Z., M.P., and G.K. are employees of, and hold equity ownership in, Bristol Myers Squibb. R.N.W–H. is an employee of PPD Development LP.
: The protocol complied with recommendations of the 18th World Health Congress (Helsinki, 1964) and all applicable amendments. The protocol and its amendment were submitted to an institutional review board (Salus Independent Review Board, Austin, TX) for review and written approval.
: Written informed consent was obtained prior to the conduct of any study-related procedures.
: All authors critically reviewed the draft manuscript and approved the final version to be published and agree to be accountable for all aspects of the work.
